F\u00e0rmacs com l’imatinib i el plerixafor, ja disponibles en la pr\u00e0ctica cl\u00ednica per al tractament d’altres tipus de c\u00e0ncer, s\u00f3n capa\u00e7os de frenar la met\u00e0stasi associada als casos m\u00e9s agressius de carcinoma escam\u00f3s de pell. Aquesta \u00e9s la conclusi\u00f3 d’un estudi que s\u2019acaba de publicar a la revista Oncogene, elaborat pels investigadors Adri\u00e0 Bernat, Pilar Simon i Vict\u00f2ria da Silva del grup liderat per la Dra. Purificaci\u00f3 Mu\u00f1oz a l’Institut de Recerca Biom\u00e8dica de Bellvitge (IDIBELL), en col\u00b7laboraci\u00f3 amb investigadors de l’Hospital Universitari de Bellvitge i del programa ProCURE (IDIBELL-ICO).<\/p>\n
\u00a0<\/p>\n
El carcinoma escam\u00f3s \u00e9s el segon tumor de pell m\u00e9s freq\u00fcent. La majoria dels casos es tracten quir\u00fargicament, per\u00f2 en un percentatge de pacients el tumor reapareix un temps despr\u00e9s de la intervenci\u00f3. Aquests tumors recurrents creixen de forma m\u00e9s agressiva i s\u00f3n considerats d’alt risc per la seva capacitat de generar met\u00e0stasi. Habitualment, aquests casos es tracten amb quimioter\u00e0pia convencional i\/o radioter\u00e0pia, tractaments que solen tenir escassos beneficis cl\u00ednics. \u00a0<\/p>\n
\u00a0<\/p>\n
Des de fa uns anys, es coneix que la majoria dels tumors contenen una poblaci\u00f3 de c\u00e8l\u00b7lules tumorals anomenades c\u00e8l\u00b7lules mare del tumor, que s\u00f3n responsables del creixement del tumor i del desenvolupament de met\u00e0stasis. Estudis previs del grup de la Dra. Mu\u00f1oz van demostrar que les caracter\u00edstiques d\u2019aquestes c\u00e8l\u00b7lules mare tumorals canvien a mesura que els carcinomes progressen a carcinomes de grau avan\u00e7at i metast\u00e0tics. No obstant aix\u00f2, es desconeixen els mecanismes que promouen la invasi\u00f3 i la disseminaci\u00f3 d’aquestes c\u00e8l\u00b7lules, processos clau en la generaci\u00f3 de met\u00e0stasis.<\/p>\n
\u00a0<\/p>\n
Ara, els estudis d’aquest equip d’investigadors demostren que les c\u00e8l\u00b7lules mare dels tumors avan\u00e7ats indueixen l’expressi\u00f3 de SDF-1 com a conseq\u00fc\u00e8ncia de l’activaci\u00f3 aberrant de la via de senyalitzaci\u00f3 guiada per la prote\u00efna de membrana PDGFR. SDF-1 \u00e9s una prote\u00efna que se secreta i s’uneix a CXCR4, activant aquest receptor present a la membrana de les c\u00e8l\u00b7lules mare tumorals. \u201cHem observat que l’activaci\u00f3 de CXCR4 estimula la capacitat invasiva de les c\u00e8l\u00b7lules tumorals i potencia el desenvolupament de met\u00e0stasi de pulm\u00f3 en models de ratol\u00ed de carcinoma escam\u00f3s avan\u00e7at de pell\u201d, explica la Dra. Mu\u00f1oz. \u201cPer tant, podem afirmar que l’activitat coordinada de les vies de senyalitzaci\u00f3 de PDGFR i CXCR4 a les c\u00e8l\u00b7lules mare del c\u00e0ncer promou el desenvolupament de met\u00e0stasi\u201d, afegeix.<\/p>\n
\u00a0<\/p>\n
“A continuaci\u00f3, ens v\u00e0rem preguntar si aquestes vies tamb\u00e9 estaven activades en les c\u00e8l\u00b7lules tumorals dels carcinomes de pell m\u00e9s agressius de pacients, la qual cosa podria obrir noves oportunitats terap\u00e8utiques per a aquests pacients” comenta Adri\u00e0 Bernat. Per estudiar la rellev\u00e0ncia d’aquestes vies en pacients, es van utilitzar models PDXs (xenografs derivats de pacients) generats en el mateix laboratori implantant mostres de carcinoma escam\u00f3s cedides pels pacients en ratolins immunodeficients.<\/p>\n
\u00a0<\/p>\n
“V\u00e0rem observar que el tractament d’aquests carcinomes avan\u00e7ats de pacients amb inhibidors de PDGFR (imatinib) i de CXCR4 (plerixafor) bloquejava el desenvolupament de met\u00e0stasis de pulm\u00f3”, explica la Dra. Mu\u00f1oz. \u201cPer tant, els resultats d’aquests estudis precl\u00ednics indiquen que els f\u00e0rmacs que inhibeixen PDGFR i CXCR4, i que s\u2019empren actualment per al tractament d’altres tipus de c\u00e0ncer, podrien ser efectius per al tractament de pacients amb carcinomes avan\u00e7ats de pell, per combatre la generaci\u00f3 de met\u00e0stasis i millorar la superviv\u00e8ncia d’aquests pacients\u201d, conclou.<\/p>\n
\u00a0<\/p>\n
L\u2019estudi ha estat finan\u00e7at amb fons del Ministeri de Ci\u00e8ncia i Innovaci\u00f3 d’Espanya i del CERCA (Generalitat de Catalunya).
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"
L\u2019activitat coordinada de les vies de senyalitzaci\u00f3 de PDGFR i CXCR4 a les c\u00e8l\u00b7lules mare del c\u00e0ncer potencia el desenvolupament de met\u00e0stasis en carcinomes avan\u00e7ats de pell<\/p>\n","protected":false},"author":6,"featured_media":10502,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,357],"tags":[],"class_list":["post-7499","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-envelliment-i-cancer"],"publishpress_future_action":{"enabled":false,"date":"2025-01-01 10:23:31","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7499"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7499\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10502"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7499"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7499"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}